FDA Panel Crushes AstraZeneca’s Hopes For Olaparib Accelerated Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic Drugs Advisory Committee members cite concerns about toxicities, both mild and severe, in the maintenance setting; they also question the reliability of the 7.1-month median progression-free survival benefit seen in a subgroup of ovarian cancer patients.